Floatz logo

nt 201

Chronic Troublesome Sialorrhea

Merz Pharmaceuticals GmbHPhase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Chronic Troublesome Sialorrhea cohort.

Asset / SponsorPhaseRating
INCOBOTULINUMTOXINA
Merz Pharmaceuticals GmbH
Phase 3BB

Same molecule, other indications

nt 201 is also rated in:

Intellectual DisabilityDormant
BB
Indicative ·
64 / 100
View asset →
cerebral palsyDormant
B
Indicative ·
62 / 100
View asset →
traumatic brain injuryDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →